NFATc1 in inflammatory and musculoskeletal conditions

Advances in Experimental Medicine and Biology

Volumn 658, Issue , 2010, Pages 69-75

  Aliprantis, Antonios O ^a   Glimcher, Laurie H ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NONE

Author keywords

Hair follicle; NFATc1; Osteoclast

Indexed keywords

COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR NFATC1; UNCLASSIFIED DRUG;

ALBERS SCHOENBERG DISEASE; BONE MASS; BONE REMODELING; CELL DIFFERENTIATION; CELL LINEAGE; CONFERENCE PAPER; DEVELOPMENTAL GENE; FIBROUS DYSPLASIA; GENE FREQUENCY; HAIR FOLLICLE; HAIR GROWTH; HUMAN; INFLAMMATORY DISEASE; MISSENSE MUTATION; MOLECULAR DYNAMICS; MUSCULOSKELETAL DISEASE; NONHUMAN; OSSIFICATION; OSTEOCLAST; OSTEOCLASTOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; SH3BP2 GENE;

ANIMALS; CALCINEURIN; HAIR FOLLICLE; HUMANS; INFLAMMATION; MUSCULOSKELETAL DISEASES; NFATC TRANSCRIPTION FACTORS; OSTEOGENESIS;

VERTEBRATA;

EID: 79959560400     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1050-9_8     Document Type: Conference Paper

References (52)

1. Aliprantis, A.O., Ueki, Y., Sulyanto, R. et al. (2008). NFATc1 represses osteoprotegerin during osteoclastogenesis and dissociates systemic osteopenia from inflammation in cherubism. J Clin Invest, 118(11):377-389.
2. Arron, J.R.,Winslow,M.M., Polleri, A. et al. (2006). NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. Nature, 441:595-600. (Pubitemid 43927286)
3. Asagiri, M., & Takayanagi, H. (2007). The molecular understanding of osteoclast differentiation. Bone, 40:251-264. (Pubitemid 46054562)
4. Asagiri, M., Sato, K., Usami, T. et al. (2005). Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med, 202:1261-1269. (Pubitemid 41586956)
5. Atkins, G.J., Bouralexis, S., Haynes, D.R. et al. (2001). Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. Bone, 28:370-377. (Pubitemid 32385408)
6. Boyle, W.J., Simonet, W.S., & Lacey, D.L. (2003). Osteoclast differentiation and activation. Nature, 423:337-342. (Pubitemid 40852708)
7. Carlsten, H. (2005). Immune responses and bone loss: the estrogen connection. Immunol Rev, 208:194-206. (Pubitemid 41746394)
8. Chang, C.P., Neilson, J.R., Bayle, J.H. et al. (2004). A field of myocardial-endocardial NFAT signaling underlies heart valve morphogenesis. Cell, 118:649-663. (Pubitemid 39179716)
9. Crotti, T.N., Flannery, M., Walsh, N.C. et al. (2006). NFATc1 regulation of the human beta3 integrin promoter in osteoclast differentiation. Gene, 372:92-102.
10. Fuller, K.,Wong, B., Fox, S. et al. (1998). TRANCE is necessary and sufficient for steoblastmediated activation of bone resorption in osteoclasts. J.Exp.Med, 188:997-1001. (Pubitemid 28433427)
11. Graef, I.A., Chen, F., & Crabtree, G.R. (2001). NFAT signaling in vertebrate development. Curr Opin Genet Dev, 11:505-512. (Pubitemid 32800723)
12. Graef, I.A., Wang, F., Charron, F. et al. (2003). Neurotrophins and netrins require calcineurin/ NFAT signaling to stimulate outgrowth of embryonic axons. Cell, 113:657-670. (Pubitemid 36694190)
13. Gwack, Y., Sharma, S., Nardone, J. et al. (2006). A genome-wide Drosophila RNAi screen identifies DYRK-family kinases as regulators of NFAT. Nature, 441:582-583.
14. Hirotani, H., Tuohy, N.A., Woo, J.T. et al. (2004). The calcineurin/nuclear factor of activated T cells signaling pathway regulates osteoclastogenesis in RAW264.7 cells. J Biol Chem, 279:13984-13992. (Pubitemid 38468932)
15. Hodge, M.R., Ranger, A.M., Charles de la Brousse, F. et al. (1996). Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice. Immunity, 4:397-405. (Pubitemid 26174981)
16. Hogan, P.G., Chen, L., Nardone, J. et al. (2003). Transcriptional regulation by calcium, calcineurin, and NFAT. Genes Dev, 17:2205-2232. (Pubitemid 37128637)
17. Horsley, V., Aliprantis, A.O., Polak, L. et al. (2008). NFATc1 balances quiescence and proliferation of skin stem cells. Cell, 132:299-310. (Pubitemid 351172432)
18. Jimi, E., & Ghosh, S. (2005). Role of nuclear factor-kappaB in the immune system and bone. Immunol Rev, 208:80-87. (Pubitemid 41746386)
19. Kaminuma, O., Kitamura, F., Kitamura, N. et al. (2008). Differential contribution of NFATc2 and NFATc1 to TNF-alpha gene expression in T cells. J Immunol, 180:319-326.
20. Karsenty, G., & Wagner, E.F. (2002). Reaching a genetic and molecular understanding of skeletal development. Dev Cell, 2:389-406. (Pubitemid 34436569)
21. Kim, K., Kim, J.H., Lee, J. et al. (2005a). Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activationinduced cytokine-mediated osteoclastogenesis. J Biol Chem, 280:35209-35216. (Pubitemid 41532708)
22. Kim, Y., Sato, K., Asagiri, M. et al. (2005b). Contribution of nuclear factor of activated T cells c1 to the transcriptional control of immunoreceptor osteoclast-associated receptor but not triggering receptor expressed by myeloid cells-2 during osteoclastogenesis. J Biol Chem, 280:32905-32913. (Pubitemid 41368340)
23. Koga, T., Inui, M., Inoue, K. et al. (2004). Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature, 428:758-763. (Pubitemid 38508286)
24. Kong, Y.Y., Yoshida, H., Sarosi, I. et al. (1999). OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature, 397:315-323.
25. Liu, B., Yu, S.F., & Li, T.J. (2003). Multinucleated giant cells in various forms of giant cell containing lesions of the jaws express features of osteoclasts. J Oral Pathol Med, 32:367-375. (Pubitemid 36781536)
26. Lorenzo, J., & Choi, Y. (2005). Osteoimmunology. Immunol Rev, 208:5-6. (Pubitemid 41746380)
27. Luisde la Pompa, J., Timmerman, L.A., Takimoto, H. et al. (1998). Role of the NF-ATc transcription factor in morphogenesis of cardiac valves and septum. Nature, 392:182-186. (Pubitemid 28162791)
28. Peng, S.L., Gerth, A.J., Ranger, A.M. et al. (2001). NFATc1 and NFATc2 together control both T and B cell activation and differentiation. Immunity, 14:13-20. (Pubitemid 32144683)
29. Phillips, K., Aliprantis, A., & Coblyn, J. (2006). Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. Drugs Aging, 23:773-779. (Pubitemid 44664668)
30. Ranger, A.M., Grusby, M.J., Hodge, M.R. et al. (1998a). The transcription factor NF-ATc is essential for cardiac valve formation. Nature, 392:186-190. (Pubitemid 28162792)
31. Ranger, A.M., Hodge, M.R., Gravallese, E.M. et al. (1998b). Delayed lymphoid repopulation with defects in IL-4-driven responses produced by inactivation of NFATc. Immunity, 8:125-134. (Pubitemid 28097830)
32. Ranger, A.M., Gerstenfeld, L.C., Wang, J. et al. (2000). The transcription factor NFATp is a repressor of chondrogenesis. J Exp Med, 191:9-21.
33. Rho, J., Takami, M., & Choi, Y. (2004). Osteoimmunology: interactions of the immune and skeletal systems. Mol Cells, 17:1-9. (Pubitemid 39137036)
34. Sharma, S.M., Bronisz, A., Hu, R. et al. (2007). MITF and PU.1 recruit p38 MAPK and NFATc1 to target genes during osteoclast differentiation. J Biol Chem, 282:15921-15929. (Pubitemid 47093311)
35. Shaw, J., Utz, P., Durand, D. et al. (1988). Identification of a putative regulator of early T cell activation genes. Science, 241:202-205.
36. Simonet, W.S., Lacey, D.L., Dunstan, C.R. et al. (1997). Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell, 89:309-319. (Pubitemid 27199902)
37. Takayanagi, H., Sato, K., Takaoka, A. et al. (2005). Interplay between interferon and other cytokine systems in bone metabolism. Immunol Rev, 208:181-193. (Pubitemid 41746393)
38. Takayanagi, H., Kim, S., Koga, T. et al. (2002). Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell, 3:889-901. (Pubitemid 35460788)
39. Tanaka, S., Nakamura, K., Takahasi, N. et al. (2005). Role of RANKL in physiological and pathological bone resorption and therapeutics targeting the RANKL-RANK signaling system. Immunol Rev, 208:30-49. (Pubitemid 41746383)
40. Tanaka, S., Takahashi, N., Udagawa, N. et al. (1993).Macrophage colony-stimulating factor is indispensable for both proliferation and differentiation of osteoclast progenitors. J Clin Invest, 91:257-263. (Pubitemid 23037280)
41. Tolar, J., Teitelbaum, S.L., & Orchard, P.J. (2004). Osteopetrosis. N Engl J Med, 351: 2839-2849.
42. Tsytsykova, A.V., & Goldfeld, A.E. (2000). Nuclear Factor of Activated T Cells Transcription Factor NFATp Controls Superantigen-induced Lethal Shock. J Exp Med, 192:581-586. (Pubitemid 30666259)
43. Ueki, Y., Tiziani, V., Santanna, C. et al. (2001). Mutations in the gene encoding c-Abl-binding protein SH3BP2 cause cherubism. Nat Genet, 28:125-126. (Pubitemid 32538054)
44. Ueki, Y., Lin, C.Y., Senoo, M. et al. (2007). Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 " cherubism" mice. Cell, 128:71-83. (Pubitemid 46048888)
45. Wada, T., Nakashima, T., Hiroshi, N. et al. (2006). RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med, 12:17-25. (Pubitemid 43089652)
46. Wagner, E.F., & Eferl, R. (2005). Fos/AP-1 proteins in bone and the immune system. Immunol Rev, 208:126-140. (Pubitemid 41746389)
47. Wein, M.N., Jones, D.C., & Glimcher, L.H. (2005). Turning down the system: counterregulatory mechanisms in bone and adaptive immunity. Immunol Rev, 208:66-79. (Pubitemid 41746385)
48. Winslow, M.M., Pan, M., Starbuck, M. et al. (2006). Calcineurin/NFAT signaling in osteoblasts regulates bone mass. Dev Cell, 10:771-782. (Pubitemid 43779111)
49. Wu, H., Peisley, A., Graef, I.A. et al. (2007). NFAT signaling and the invention of vertebrates. Trends Cell Biol, 17:251-260. (Pubitemid 46829850)
50. Xing, L., Schwarz, E.M., & Boyce, B.F. (2005). Osteoclast precursors, RANKL/RANK, and immunology. Immunol Rev, 208:19-29. (Pubitemid 41746382)
51. Yamamoto, S., & Kato, R. (1994). Hair growth-stimulating effects of cyclosporin A and FK506, potent immunosuppressants. J Dermatol Sci, 7(Suppl):S47-S54.
52. Yasuda, H., Shima, N., Nakagawa, N. et al. (1998). Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA, 95:3597-3602.